Alembic skids 4.96% to Rs 126.35 after the company's consolidated net profit slumped 93.4% to Rs 3.64 crore on 151.7% increase in net sales to Rs 28.89 crore in Q4 March 2021 over Q4 March 2020.
Profit before tax dropped 91.7% to Rs 4.59 crore in Q4 March 2021 as against Rs 55.63 crore in Q4 March 2020.
The company's consolidated net profit tanked 85.12% to Rs 13.84 crore on a 0.55% rise in revenue from operations to Rs 73.52 crore in FY 2021 over FY 2020. Profit before tax tumbled 81.71% to Rs 17.04 crore in FY 2021 from Rs 93.17 crore in FY 2020.
The board has recommended a dividend of Rs 0.20 for the year ended 31 March 2021.
Alembic engages in pharmaceuticals, real estate and power assets business.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app